JR-441

JCR Pharmaceuticals Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	JR-441
Also known as	posnafusp alfa
Sponsor	JCR Pharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

JR-441 CI brief — competitive landscape report
JR-441 updates RSS · CI watch RSS
JCR Pharmaceuticals Co., Ltd. portfolio CI